Algernon Pharmaceuticals Inc. Archives

Debra BorchardtAugust 21, 2024

Algernon is progressing in its study of DMT for stroke victims.

Debra BorchardtJune 5, 2023

Algernon Pharmaceuticals Inc. (CSE: AGN) (OTCQB: AGNPF)announced that its subsidiary Algernon NeuroScience (AGN Neuro), has successfully completed dosing of the third and planned final cohort in its escalating dose Phase 1 clinical study of an intravenous (IV) formulation of AP-188 (DMT). AGN Neuro is the world’s first company to investigate DMT for both the treatment […]

Dave HodesJanuary 25, 2023

Traditional tactics aren't always the most effective ways to raise capital.

StaffJanuary 11, 2023

The Daily Hit is a recap of cannabis business news for Jan. 11, 2023. ON THE SITE Connecticut Recreational Cannabis Sales Top $250,000 on Day One According to Biotrack, the cannabis technology platform Connecticut uses to trace marijuana inventory from seed to sale, those seven retailers passed the $250,000 mark by 5 p.m. after just […]

Dave HodesJanuary 11, 2023

Algernon wants to use psychedelics as a therapy for stroke victims.

Adam JacksonOctober 24, 2022

Canadian clinical stage drug development company, Algernon Pharmaceuticals Inc. (CSE: AGN) (OTCQB: AGNPF), has entered a clinical trial agreement with Yale University to study DMT for the treatment of depression. Algernon will provide DMT for the study in return for intellectual property rights with Yale around the clinical use of the drug. The company will […]